Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients
Authors:
- 1 January 1995
- journal article
- clinical trial
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 41 (1) , 29-36
Abstract
A phase I trial of a murine anti-ganglioside (GD2) monoclonal antibody (mAb) 14G2a was conducted in 14 neuroblastoma patients and 1 osteosarcoma patient to assess its safety, toxicity and pharmacokinetics in pediatric patients. The pharmacokinetics of mAb 14G2a were biphasic with at 1 2/α of 2.8±2.8 h and at 1 2/β of 18.3±11.8 h. In general,t 1 2/β was dose-dependent with a level of significance ofP=0.036, and it reached a plateau at doses of 250 mg/m2 or more. Overall the peak serum levels were dose-dependent atP2 and 250 mg/m2. The latter two suggest a saturable mechanism for mAb elimination. In addition, peak serum concentrations were observed earlier at higher mAb doses, which indicates the achievement of a steady state. Thet 1 2/β of mAb 14G2a in children appears to be shorter than in adults. Furthermore, 2 patients demonstrated a considerable decrease int 1 2/β following retreatment with 14G2a. This was paralleled by high human anti-(mouse Ig) antibody levels. This study represents the first comprehensive analysis of murine mAb pharmacokinetics in children and will be useful in the future design of mAb therapy.Keywords
This publication has 31 references indexed in Scilit:
- Monoclonal antibodies in cancer detection and therapyThe American Journal of Medicine, 1993
- A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2aCancer Immunology, Immunotherapy, 1992
- PHASE I TRIAL OF MURINE ANTI-GANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (Mab) 14G2A IN CANCER PATIENTSJournal of Immunotherapy, 1992
- Human IgM Monoclonal Antibody 16.88: Pharmacokinetics and Immunogenicity in Colorectal Cancer PatientsJNCI: Journal of the National Cancer Institute, 1991
- Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patientsJournal of Autoimmunity, 1991
- Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.Proceedings of the National Academy of Sciences, 1989
- Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.Proceedings of the National Academy of Sciences, 1985
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975
- Assessment of Pharmacokinetic Constants from Postinfusion Blood Curves Obtained after I.V. InfusionJournal of Pharmaceutical Sciences, 1970
- Radioimmunoassay: A Method for Human Chorionic Gonadotropin and Human Luteinizing Hormone1Endocrinology, 1966